Back to User profile » Dr Andrea Casadei-Gardini
Papers published by Dr Andrea Casadei-Gardini:
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Celsa C, Foschi FG, Silletta M, Amoruso DC, Rimini M, Bruccoleri M, Tortora R, Campani C, Soldà C, Viola MG, Forgione A, Conti F, Salani F, Catanese S, Giacchetto CM, Fulgenzi C, Coppola C, Lampertico P, Pellino A, Rancatore G, Cabibbo G, Ratti F, Pedica F, Della Corte A, Colombo M, De Cobelli F, Aldrighetti L, Cascinu S, Casadei-Gardini A
Cancer Management and Research 2021, 13:9379-9389
Published Date: 24 December 2021
Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
De Matteis S, Ghetti M, Gramantieri L, Marisi G, Casadei-Gardini A
OncoTargets and Therapy 2021, 14:4305-4308
Published Date: 30 July 2021
Prognostic Role of a New Inflammatory Index with Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase (CII: Colon Inflammatory Index) in Patients with Metastatic Colorectal Cancer: Results from the Randomized Italian Trial in Advanced Colorectal Cancer (ITACa) Study [Corrigendum]
Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, Passardi A
Cancer Management and Research 2020, 12:541-542
Published Date: 23 January 2020
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]
Casadei-Gardini A, Montagnani F, Casadei C
Cancer Management and Research 2019, 11:5123-5124
Published Date: 25 June 2019
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, Passardi A
Cancer Management and Research 2019, 11:4357-4369
Published Date: 10 May 2019
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell’Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P
Cancer Management and Research 2019, 11:3631-3642
Published Date: 26 April 2019
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
Casadei Gardini A, Puzzoni M, Montagnani F, Marisi G, Tamburini E, Cucchetti A, Solaini L, Foschi FG, Conti F, Ercolani G, Cascinu S, Scartozzi M
OncoTargets and Therapy 2019, 12:2981-2988
Published Date: 24 April 2019
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P
Cancer Management and Research 2018, 10:5659-5666
Published Date: 14 November 2018
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B
OncoTargets and Therapy 2018, 11:7315-7321
Published Date: 25 October 2018
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
Casadei Gardini A, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G, Valgiusti M, Passardi A, Frassineti GL, Scarpi E
OncoTargets and Therapy 2018, 11:6555-6567
Published Date: 5 October 2018
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial
Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A
OncoTargets and Therapy 2018, 11:5261-5268
Published Date: 29 August 2018